210 related articles for article (PubMed ID: 15614737)
1. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
Bakir K; Koçer NE; Deniz H; Güldür ME
Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
3. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma.
Khoor A; Whitsett JA; Stahlman MT; Olson SJ; Cagle PT
Hum Pathol; 1999 Jun; 30(6):695-700. PubMed ID: 10374779
[TBL] [Abstract][Full Text] [Related]
4. [Surfactant protein and thyroid transcription factor 1 in pleuro-pulmonary neoplasia. Immunohistochemical study].
Dessy E; Falleni M; Del Curto B; Braidotti P; Pietra GG
Pathologica; 2000 Dec; 92(6):496-502. PubMed ID: 11234300
[TBL] [Abstract][Full Text] [Related]
5. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.
Di Loreto C; Puglisi F; Di Lauro V; Damante G; Beltrami CA
Cancer Lett; 1998 Feb; 124(1):73-8. PubMed ID: 9500194
[TBL] [Abstract][Full Text] [Related]
6. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2000 Apr; 24(4):598-606. PubMed ID: 10757409
[TBL] [Abstract][Full Text] [Related]
7. Expression of thyroid transcription factor-1 in malignant pleural effusions.
Khoor A; Byrd-Gloster AL; Nicosia SV
Pathol Oncol Res; 2011 Jun; 17(2):263-7. PubMed ID: 20848248
[TBL] [Abstract][Full Text] [Related]
8. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
9. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
10. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
11. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases.
Zamecnik J; Kodet R
Virchows Arch; 2002 Apr; 440(4):353-61. PubMed ID: 11956814
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
[TBL] [Abstract][Full Text] [Related]
13. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.
Afify AM; al-Khafaji BM
Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029
[TBL] [Abstract][Full Text] [Related]
15. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
[TBL] [Abstract][Full Text] [Related]
16. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].
Zou SM; Lin DM; Lü N; Liu XY; Wen P; Liu FS
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1350-2. PubMed ID: 12930693
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
18. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
19. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
20. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
